As long as the FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone remain in place, it creates an unnecessary barrier to access safe medication for abortion and miscarriage care. This article discusses why it’s critical to permanently remove the REMS to reduce the disproportionate harms of abortion restrictions on communities of color, and advance equity in and access to timely and essential reproductive health care.